NASDAQ: GNLX - Genelux Corporation

Yield per half year: +45.03%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Genelux Corporation

Extended chart Simple chart
Financial Markets by TradingView

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC.

more details
Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-01-26
ISIN US36870H1032
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.genelux.com
Цена ао 5.95
Change price per day: +0.813% (2.46)
Change price per week: +9.25% (2.27)
Change price per month: -7.81% (2.69)
Change price per 3 month: +14.29% (2.17)
Change price per half year: +45.03% (1.71)
Change price per year: -82.3% (14.01)
Change price per 3 year: 0% (2.48)
Change price per 5 year: 0% (2.48)
Change price per 10 year: 0% (2.48)
Change price per year to date: -0.4016% (2.49)
All parameters

Underestimation

Title Value Grade
P/S 2158.4 1
P/BV 18.84 1
P/E 0 0
EV/EBITDA -15.55 0
Total: 2.13

Efficiency

Title Value Grade
ROA, % -101.45 0
ROE, % -145.31 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1088 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -98.46 0
Yield Ebitda, % 154.39 10
Yield EPS, % 135.19 10
Total: 8
More

Institutions Volume Share, %
Blackrock Inc. 1196123 4.48
Vanguard Group Inc 980993 3.67
Geode Capital Management, LLC 386634 1.45
State Street Corporation 231065 0.86
AE Wealth Management LLC 194875 0.73
Northern Trust Corporation 160816 0.6
Provident Wealth Management, LLC 157137 0.59
Charles Schwab Investment Management, Inc. 149604 0.56
Bank Of New York Mellon Corporation 53841 0.2
AMG National Trust Bank 50346 0.19

ETF Share, % Profitability for 1 year, % Dividends, %
Range Cancer Therapeutics ETF 0.53743 47.24 0.11955
iShares Micro-Cap ETF 0.01521 17.09 1.54048
Schwab U.S. Small-Cap ETF 0.0013 17.47 1.51433



Head Job title Payment Year of birth
Mr. Thomas Zindrick J.D. Chairman, CEO & President 570.99k 1959 (66 years)
Mr. Sean Ryder J.D. General Counsel & Corporate Secretary 380k 1969 (56 years)
Ms. Lourie S. Zak Chief Financial Officer 346.19k 1963 (62 years)
Dr. Joseph Cappello Ph.D. Chief Technical Officer 213.08k 1957 (68 years)
Dr. Yong Yu Ph.D. Senior Vice President of Clinical Development 242.62k 1971 (54 years)
Prof. Paul Scigalla M.D., Ph.D. Chief Medical Officer N/A 1945 (80 years)
Mr. Ralph Smalling B.Sc. VP & Head of Regulatory Affairs N/A 1957 (68 years)
Ms. Caroline Jewett VP & Head of Quality 269.26k 1965 (60 years)

Address: United States, Westlake Village. CA, 2625 Townsgate Road - open in Google maps, open in Yandex maps
Website: https://www.genelux.com